Search results
Moderna Stock Rebounds From Its RSV Vaccine Fallout — Is It A Buy, Again?
Investor's Business Daily· 1 day agoModerna stock tumbled — and then rebounded — after the Food and Drug Administration delayed its RSV...
A Novel Broad-Spectrum Antiviral with Activity Against RSV
Digital Journal· 2 days agoIn this study, extended dosing of NV-387 given orally was compared with a high dose of ribavirin given orally for the same duration. Two doses were given on first day of dosing followed by one ...
NanoViricides unveils new data showing lead drug asset’s strong activity against RSV
Proactive Investors· 2 days agoThe company said that animals lethally infected in their lungs with RSV achieved full survival upon...
NanoViricides Has Filed its Quarterly Report
The Sacramento Bee· 13 hours agoSHELTON, CT / ACCESSWIRE / May 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly ...
Moderna Stock Slips as FDA Delays RSV Vaccine Approval
Investopedia· 6 days agoModerna (MRNA) shares lost ground in intraday trading Friday as the biotech’s effort to move beyond...
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 1 day agoIt will cost $3.5 million for a one-time treatment. And European regulators gave Pfizer the nod for...
Moderna’s First Vaccine Was a Big Hit. Its Second Is a Let Down
Bloomberg via Yahoo Finance· 7 days ago(Bloomberg) -- Moderna Inc.’s pioneering Covid shot turned the company into a nearly $200 billion...
The 3 Most Undervalued Pharma Stocks to Buy in May 2024
InvestorPlace via Yahoo Finance· 7 days agoHere’s a question for you: What determines the value of a drug? Is it the number of lives it saves...
NanoViricides CEO discusses NV-387’s broad-spectrum antiviral potential
Proactive Investors· 2 days agoNanoViricides (NYSE-A:NNVC) has released a slew of new data supporting the safety and ultra-broad...
Moderna’s mRNA dreams meet reality with first post-COVID shot - The Boston Globe
The Boston Globe· 6 days agoModerna’s stock dropped 45 percent last year, making it the worst-performing large biotech in the...